Resource Type

Journal Article 791

Year

2024 1

2023 62

2022 73

2021 66

2020 55

2019 55

2018 49

2017 50

2016 28

2015 54

2014 34

2013 32

2012 22

2011 30

2010 28

2009 29

2008 26

2007 30

2006 9

2005 4

open ︾

Keywords

lung cancer 16

fuel cell 13

immunotherapy 8

hepatocellular carcinoma 6

solar cell 6

hematopoietic stem cell transplantation 5

hydrogen energy 5

stem cell 5

cell proliferation 4

chemotherapy 4

control 4

durability 4

microbial fuel cell 4

solid oxide fuel cell 4

COVID-19 3

cancer immunotherapy 3

development 3

different 3

non-linear 3

open ︾

Search scope:

排序： Display mode:

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamousnon-small-cell lung cancer: a retrospective analysis

Frontiers of Medicine 2022, Volume 16, Issue 4,   Pages 610-617 doi: 10.1007/s11684-021-0827-8

Abstract: anti-VEGF monoclonal antibody, has significantly improved the clinical outcomes of patients with advanced non-squamous

Keywords： bevacizumab     elderly patient     advanced non-small-cell lung cancer     overall survival     toxicity    

HTML PDF Collect

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Frontiers of Medicine 2013, Volume 7, Issue 2,   Pages 157-171 doi: 10.1007/s11684-013-0272-4

Abstract:

Non-small-cell lung cancer (NSCLC) is the most common cause of premature death among the malignant

Keywords： non-small-cell lung cancer     molecular typing     individualized medicine     molecular-targeted therapy     gene expression    

HTML PDF Collect

Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-celllung cancer

Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu

Frontiers of Medicine 2020, Volume 14, Issue 1,   Pages 60-67 doi: 10.1007/s11684-019-0694-8

Abstract: Moreover, C620-0696 was cytotoxic in BPTF with a high expression of non-small-cell lung cancer (NSCLCpartially inhibited the migration and colony formation of NSCLC cells owing to apoptosis induction and cellpresents an effective strategy to target a bromodomain factor-mediated tumorigenesis in cancers with small

Keywords： BPTF     small molecule     epigenetics     non-small-cell lung cancer    

HTML PDF Collect

Expression of Syk in non-small cell lung cancer and its relationship with clinicopathological parameters

Fen LAN, Shengdao XIONG, Weining XIONG, Guopeng XU, Xiaoxia LU

Frontiers of Medicine 2009, Volume 3, Issue 1,   Pages 41-44 doi: 10.1007/s11684-009-0009-6

Abstract: This study aims to research the expression of spleen tyrosine kinase (Syk) in non-small cell lung cancerImmunohistochemistry was applied to detect the expression of Syk and p53 protein in 39 cases of NSCLC (23 cases of lungsquamous cell cancer, 16 cases of lung adenocarcinoma) and tumor-surrounding normal lung tissues.The positive rate of Syk was 46.15% (18/39) and 100% (39/39) in NSCLC and tumor-surrounding normal lungThe expression level of Syk in NSCLC was significantly lower than that in tumor-surrounding normal lung

Keywords： Syk kinase     carcinoma     non-small-cell lung     tumor suppressor protein p53    

HTML PDF Collect

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 18-42 doi: 10.1007/s11684-022-0976-4

Abstract: With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC), expanding

Keywords： non-small cell lung cancer     driver mutations     treatment strategy     resistant mechanism     immune-checkpoint    

HTML PDF Collect

Lobectomy by video-assisted thoracoscopic surgery (VATS) for early stage of non-small cell lung cancer

Min ZHU, Xiang-Ning FU, Xiao-Ping CHEN

Frontiers of Medicine 2011, Volume 5, Issue 1,   Pages 53-60 doi: 10.1007/s11684-011-0121-2

Abstract:

Video-assisted thoracoscopic surgery (VATS) provides a new approach for treating early-stage lungHowever, there is still much debate on the role of VATS in lobectomy for the treatment of lung cancerlymph node dissection, and long-term survival have made some surgeons apprehensive of its validity for lungthis paper, we review the development of thoracoscopy, the present status of VATS for early stage of non-smallcell lung cancer (NSCLC), and comparison between VATS and open thoracotomy in the management of NSCLC

Keywords： non-small cell lung cancer     video-assisted thoracoscopic surgery     lobectomy    

HTML PDF Collect

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 245-255 doi: 10.1007/s11684-009-0044-3

Abstract: Lung cancer is one of the most common human cancers and the number one cancer killer in the United StatesIn general, lung cancer includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), but NSCLC accounts for approximately 90% of lung cancer.tools, which can improve current early detection to reduce mortality from lung cancer, do not exist.These molecular markers in NSCLC demonstrated close associations with the development of lung cancer

Keywords： lung cancer     carcinoma     non-small cell lung cancer     molecular markers     targeted therapy    

HTML PDF Collect

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 105-118 doi: 10.1007/s11684-022-0934-1

Abstract: receptor (EGFR) inhibitor osimertinib (OSI) has been approved as the first-line treatment for EGFR-mutant non-smallcell lung cancer (NSCLC).

Keywords： osimertinib     anti-CD47 antibody     combination strategy     ADCP     EGFR    

HTML PDF Collect

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-likecells enriched with tumor spheroids from a non-small cell lung cancer cell line

Douglas D. Fang, Joan Cao, Jitesh P. Jani, Konstantinos Tsaparikos, Alessandra Blasina, Jill Kornmann, Maruja E. Lira, Jianying Wang, Zuzana Jirout, Justin Bingham, Zhou Zhu, Yin Gu, Gerrit Los, Zdenek Hostomsky, Todd VanArsdale

Frontiers of Medicine 2013, Volume 7, Issue 4,   Pages 462-476 doi: 10.1007/s11684-013-0270-6

Abstract: for developing more effective therapies that target highly tumorigenic and drug-resistant cancer stem celldemonstrate that a subset of cancer cells with CSC properties may be enriched into tumor spheroids under stem cellconditions from a non-small cell lung cancer cell line.00477736 enhances the anti-proliferative effect of gemcitabine against both the parental and the CSC-like cell

Keywords： drug resistance     cancer stem cell     checkpoint kinase 1 (CHK1)     PF-00477736     lung cancer     tumorigenicity    

HTML PDF Collect

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 766-772 doi: 10.1007/s11684-021-0916-8

Abstract: Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies

Keywords： anlotinib     chemotherapy     short-term relapsed     small-cell lung cancer    

HTML PDF Collect

Improved local control without elective nodal radiotherapy in patients with unresectable NSCLC treated by 3D-CRT

YANG Kunyu, LIU Li, ZHANG Tao, WU Gang, CAO Fengjun, WANG Jianhua

Frontiers of Medicine 2007, Volume 1, Issue 4,   Pages 381-385 doi: 10.1007/s11684-007-0074-7

Abstract: therapeutic results of definitive radiotherapy for patients with stage IIIA or stage IIIB unresectable non-small-celllung cancer, 55 patients with clinically inoperable advanced non-small-cell lung cancer were studiedradiotherapy (ENI group); and in the other group, elective nodal irradiation was not included in CTV (non-ENIgroup, the mean prescription dose for gross tumor volumes was 58.4 Gy, while for the patients in the non-ENI

Keywords： significant difference     irradiation     unresectable non-small-cell     induction chemotherapy     influence    

HTML PDF Collect

Fine-tuning cell organelle dynamics during mitosis by small GTPases

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 339-357 doi: 10.1007/s11684-022-0926-1

Abstract: Small GTPases belonging to the Ras superfamily regulate various cell organelles during division.Being the key regulators of membrane dynamics, the dysregulation of small GTPases is widely associatedwith cell organelle disruption in neoplastic and non-neoplastic diseases, such as cancer and AlzheimerThis review collects current knowledge on small GTPases in the regulation of cell organelles during mitosisand highlights the mediator role of small GTPase in transducing cell cycle signaling to organelle dynamics

Keywords： small GTPase     cell organelle     mitosis    

HTML PDF Collect

Discovery of small molecule degraders for modulating cell cycle

Frontiers of Medicine   Pages 823-854 doi: 10.1007/s11684-023-1027-5

Abstract: The cell cycle is a complex process that involves DNA replication, protein expression, and cell divisionDysregulation of the cell cycle is associated with various diseases.Cyclin-dependent kinases (CDKs) and their corresponding cyclins are major proteins that regulate the cell

Keywords： PROTAC     molecular glue     degrader     cell cycle     CDK     cyclin    

HTML PDF Collect

Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation

Fei Gao, Jingyu Chen, Dong Wei, Bo Wu, Min Zhou

Frontiers of Medicine 2018, Volume 12, Issue 2,   Pages 224-228 doi: 10.1007/s11684-017-0538-3

Abstract:

Bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HSCT) is aLung transplantation (LTX) has been rarely reported as a treatment option for selected HSCT recipientsOne of the recipients suffered from mild acute rejection after LTX, another suffered from primary lung

Keywords： bronchiolitis obliterans syndrome (BOS)     hematopoietic stem cell transplantation (HSCT)     lung transplantation    

HTML PDF Collect

Orlistat induces ferroptosis-like cell death of lung cancer cells

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 922-932 doi: 10.1007/s11684-020-0804-7

Abstract: synthesis is involved in the progression and treatment resistance of many types of cancers, including lung, and we found that orlistat, as a single agent, inhibited the proliferation and viabilities of lungcancer cells and induced ferroptosis-like cell death in vitro.anticancer activity of orlistat and provided the rationale for repurposing this drug for the treatment of lung

Keywords： orlistat     ferroptosis     FAF2     lung cancer    

HTML PDF Collect

Title Author Date Type Operation

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamousnon-small-cell lung cancer: a retrospective analysis

Journal Article

Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis

Yue Yu, Jie He

Journal Article

Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-celllung cancer

Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu

Journal Article

Expression of Syk in non-small cell lung cancer and its relationship with clinicopathological parameters

Fen LAN, Shengdao XIONG, Weining XIONG, Guopeng XU, Xiaoxia LU

Journal Article

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future

Journal Article

Lobectomy by video-assisted thoracoscopic surgery (VATS) for early stage of non-small cell lung cancer

Min ZHU, Xiang-Ning FU, Xiao-Ping CHEN

Journal Article

Molecular markers and pathogenically targeted therapy in non-small cell lung cancer

Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD

Journal Article

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Journal Article

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-likecells enriched with tumor spheroids from a non-small cell lung cancer cell line

Douglas D. Fang, Joan Cao, Jitesh P. Jani, Konstantinos Tsaparikos, Alessandra Blasina, Jill Kornmann, Maruja E. Lira, Jianying Wang, Zuzana Jirout, Justin Bingham, Zhou Zhu, Yin Gu, Gerrit Los, Zdenek Hostomsky, Todd VanArsdale

Journal Article

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup

Journal Article

Improved local control without elective nodal radiotherapy in patients with unresectable NSCLC treated by 3D-CRT

YANG Kunyu, LIU Li, ZHANG Tao, WU Gang, CAO Fengjun, WANG Jianhua

Journal Article

Fine-tuning cell organelle dynamics during mitosis by small GTPases

Journal Article

Discovery of small molecule degraders for modulating cell cycle

Journal Article

Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation

Fei Gao, Jingyu Chen, Dong Wei, Bo Wu, Min Zhou

Journal Article

Orlistat induces ferroptosis-like cell death of lung cancer cells

Journal Article